Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

418933

registered interest
date	15/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prescription Drugs: Internet
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to (a) reduce and (b) monitor the sale of prescription drugs on the internet.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	10263
answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>In the United Kingdom, all categories of medicines may be traded online legally but in the case of prescription only medicines (POM) and pharmacy (P) medicines, these may only be sold or supplied to the public through registered pharmacy premises (by or under the supervision of a pharmacist). Additionally, POMs may only be supplied in response to a prescription from an authorised healthcare professional.</p><p> </p><p> </p><p> </p><p>A UK registered pharmacy may have a presence on the internet; however the requirements of legislation apply equally to both UK internet pharmacies and bricks-and-mortar premises.</p><p> </p><p> </p><p> </p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) monitors the internet for websites operating outside legal requirements and, in collaboration with Internet Service Providers, takes steps to close down sites both in the UK and abroad. The MHRA has closed down 1,973 websites (including those based overseas) during 2015 alone and brought into compliance many others.</p><p> </p><p> </p><p> </p><p>The illegal sale and supply of medicines via Internet poses considerable risks to UK patients but this is in essence a global problem and the MHRA is working with other regulators, law enforcement authorities and Government Departments within the UK, European Union and elsewhere to address the complex issues involved.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 21/09/2015 14:47:22 answering member 4020 label Biography information for George Freeman
tabling member	4131 label Biography information for Jim Shannon

418935

registered interest
date	15/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Breast Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent discussions he has had with the Royal Colleges on the development and use of progesterone and tamoxifen to treat breast cancer.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	10266
answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>There have been no such discussions.</p><p> </p><p> </p><p> </p><p>Research into the use of progesterone in combination with tamoxifen for the treatment of breast cancer is still at an early stage and has not yet been trialled in humans.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 21/09/2015 14:41:04 answering member 4020 label Biography information for George Freeman
tabling member	4131 label Biography information for Jim Shannon

418936

registered interest
date	15/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Dementia: Diabetes
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with the Royal College of Physicians on a link between type 2 diabetes and dementia; and what steps he is taking to treat dementia caused in that way.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	10243
answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>NHS England is implementing the NHS Diabetes Prevention Programme, and it is possible that prevention of Type 2 diabetes may in the longer term reduce dementia risk, although at this point this is speculative rather than being based on evidence.</p><p> </p><p> </p><p> </p><p>The treatment of dementia associated with Type 2 diabetes is as for any dementia, although it is important to also address the Type 2 diabetes and vascular risk. People with dementia who also have diabetes need support to manage their condition.</p><p> </p><p> </p><p> </p><p>Improving the treatment and care of people with dementia, reducing the incidence of dementia and improving dementia research, is a key priority for the Government. That is why in February 2015, the Prime Minister launched his Challenge on Dementia 2020 as a successor to the Prime Minister’s Challenge on Dementia 2012-2015.</p><p> </p><p><strong> </strong></p><p> </p><p>My Rt. hon. Friend the Secretary of State has had and continues to have discussions on these matters with a range of organisations including the Royal College of Physicians.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 21/09/2015 15:01:16 answering member 3918 label Biography information for Jane Ellison
tabling member	4131 label Biography information for Jim Shannon

418937

registered interest
date	15/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Dementia: Vitamin D
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with the Royal College of Physicians on using vitamin D as a treatment for delaying or preventing dementia.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	10244
answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>Current evidence is not supportive of using vitamin D as a treatment for delaying or preventing dementia.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 21/09/2015 15:04:47 answering member 3918 label Biography information for Jane Ellison
tabling member	4131 label Biography information for Jim Shannon

418938

registered interest
date	15/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prescriptions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department takes to monitor the level of prescriptions issued by GPs; and if he will make a statement.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	10256
answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>Clinicians are responsible for their own treatment decisions taking any relevant guidance into account. They should always satisfy themselves that the drugs or other substances they consider appropriate for their patients can be safely prescribed, that patients are adequately monitored and that, where necessary, additional support or supervision is available.</p><p> </p><p><strong> </strong></p><p> </p><p>Within the General Medical Services (GMS) and Personal Medical Services Regulations and Alternative Provider Medical Services Directions there are clauses in relation to prescribing and dispensing. The GMS Contracts Regulations Schedule 6 Part 3 paragraph 46 says:</p><p> </p><p> </p><p> </p><p>“Excessive prescribing</p><p> </p><p>46 - (1) The contractor shall not prescribe drugs, medicines or appliances whose cost or quantity, in relation to any patient is, by reason of the character of the drug, medicine or appliance in question in excess of that</p><p> </p><p>which was reasonably necessary for the proper treatment of that patient.</p><p> </p><p> </p><p> </p><p>(2) In considering whether a contractor has breached its obligations under sub-paragraph (1) NHS England must seek the views of the Local Medical Committee (if any) for the area in which the contractor provides services under the contract.”</p><p> </p><p> </p><p> </p><p>Practitioners are encouraged to prescribe rationally and to make the best possible use of National Health Service resources.</p><p> </p><p> </p><p> </p><p>Professional bodies issue standards and/or guidance for their members on prescribing. An example of this is the General Medical <em>Council’s “Good practice in prescribing and managing medicines and devices”</em>. It provides more detailed advice on how to comply with these principles when prescribing and managing medicines and medical devices, including appliances. If clinicians act outside of this guidance they can be held to account and potentially lose their professional registration, meaning they are unable to practice.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency North East Bedfordshire answering member printed Alistair Burt question first answered 21/09/2015 15:37:56 answering member 1201 label Biography information for Alistair Burt
tabling member	4131 label Biography information for Jim Shannon

418939

registered interest
date	15/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prescription Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will hold discussions with representatives of the pharmaceuticals industry on the potential merits of the use of identity cards for the use of prescription drugs to minimise misuse of such drugs.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	10257
answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>We have no plans to do so.</p><p> </p><p> </p><p> </p><p>My Rt. hon. Friend the Home Secretary commissioned the Advisory Council on the Misuse of Drugs to explore the potential for medical and social harms arising from the diversion and illicit supply of prescription drugs.</p><p> </p><p> </p><p> </p><p>The Committee’s report is expected later this year and we will consider its conclusions carefully.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 21/09/2015 15:37:09 answering member 4020 label Biography information for George Freeman
tabling member	4131 label Biography information for Jim Shannon

418940

registered interest
date	15/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Misuse
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assistance his Department provides to people addicted to legal highs.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	10258
answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>The dependence-forming potential of many new psychoactive substances (NPS) is still largely unknown, and the number of people attending specialist drug treatment services is relatively small. If users need help, it will more likely be because they have acute NPS-related problems (eg, agitation, palpitations, seizures) and they will probably first present at accident and emergency (A&amp;E) departments.</p><p> </p><p> </p><p> </p><p>Local authorities are responsible for assessing drug treatment needs in their local areas and providing services to meet that need. This includes determining the scale of NPS use and harm in their areas and ensuring there are services to tackle that harm.</p><p> </p><p> </p><p> </p><p>Public Health England (PHE) supports local authorities in their work of assessing need and planning services, by improving data, intelligence and information sharing systems, to ensure prevention and treatment are as effective as they can be in the changing NPS market.</p><p> </p><p> </p><p> </p><p>PHE has produced an NPS toolkit for substance misuse commissioners which gives a broad overview of the challenges from NPS and provides commissioners with resources and advice to inform their work.</p><p> </p><p> </p><p> </p><p>PHE has also supported Project NEPTUNE, which is producing detailed and practical clinical guidance and tools for A&amp;E, drug treatment and other services that deal with people who have NPS problems.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 21/09/2015 14:54:24 answering member 3918 label Biography information for Jane Ellison
tabling member	4131 label Biography information for Jim Shannon

418943

registered interest
date	15/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Morquio Syndrome: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to ensure that NHS England funds homecare costs for patients currently in receipt of the Vimizim drug from BioMarin.
tabling member constituency	Leeds North West
tabling member printed	Greg Mulholland
uin	10374
answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>NHS England can confirm that it does and will continue to reimburse costs incurred by National Health Service trusts for providing homecare for patients currently in receipt of Vimizim.</p><p> </p><p> </p><p> </p><p>NHS England remains committed to supporting any additional costs associated with the delivery of Vimizim to individuals who are continuing treatment following on from the clinical trial.</p><p> </p><p> </p><p> </p><p>This message was communicated in a letter from the Director of Specialised Commissioning, Richard Jeavons, to the Chief Executive of the Society for Mucopolysaccharide Diseases (The MPS Society), Christine Lavery, on 17 August.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 21/09/2015 14:34:02 answering member 4020 label Biography information for George Freeman
tabling member	1540 label Biography information for Greg Mulholland

418944

registered interest
date	15/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS England: Correspondence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will instruct the Director of Specialised Commissioning at NHS England to respond to the letter from the MPS Society dated 20 August 2015.
tabling member constituency	Leeds North West
tabling member printed	Greg Mulholland
uin	10375
answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>The Director of Specialised Commissioning at NHS England, Richard Jeavons, has confirmed that he has received the letter from the MPS society dated 20 August.</p><p> </p><p> </p><p> </p><p>A response to the correspondence was sent on 16 September following Mr Jeavons’ return from a period of annual leave.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 21/09/2015 15:06:36 answering member 4020 label Biography information for George Freeman
tabling member	1540 label Biography information for Greg Mulholland

418946

registered interest
date	15/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cardiovascular System: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether his Department plans to provide renal denervation for the treatment of high blood pressure on the NHS.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	10267
answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>NHS England’s Clinical Commissioning Policy Statement <em>Renal Denervation for Resistant Hypertension</em>, published in April 2013, states that NHS England does not routinely commission renal denervation as a treatment for resistant hypertension.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 21/09/2015 14:59:39 answering member 3918 label Biography information for Jane Ellison
tabling member	4131 label Biography information for Jim Shannon